A Double-blind, Placebo-controlled, Randomized Trial of XP-828L (800 mg) on the Quality of Life and Clinical Symptoms of Patients with Mild-to-Moderate Psoriasis
Share this article:
Abstract
In a placebo-controlled clinical trial, the dietary supplement XP828L (commercialized as DermylexTM) demonstrated potential to reduce symptoms associated with mild-to-moderate psoriasis at a dose regimen of 5 g daily for 56 days. However, recent in vivo data in humans and animals suggest a daily dose of 800 mg could be more efficient than a 5-g dose. However, no well-structured clinical study has confirmed this hypothesis. The goal of the present study is to examine the effect of XP-828L at a daily dose of 800 mg on the quality of life and disease severity in patients with mild-to-moderate psoriasis. XP-828L at 800 mg per day (n=16) or placebo (n=10) was given orally for 56 days. Efficacy was measured by the Dermatology Life Quality Index (DLQI), Psoriasis Area and Severity Index (PASI), and itching sensation scores at day 1 and day 56. The DLQI and PASI scores and itching sensation decreased significantly by day 56 in subjects taking XP-828L compared to placebo (p<0.05). In summary, daily administration of 800 mg XP-828L for 56 days is adequate to improve the quality of life and decrease disease severity in patients with mild-to-moderate psoriasis. (Altern Med Rev 2008;13(2):145-152)[/vc_column_text][/vc_column_inner][vc_column_inner width="1/6"][vc_btn title="Download PDF" color="primary" link="url:%2Fwp-content%2Fuploads%2F2019%2F02%2Fv13-2-145.pdf|title:Download%20PDF|target:%20_blank|" el_class="resource-download"][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row]
